Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 378

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Open access
Prados, Michael D., Chang, Susan M., Butowski, Nicholas, DeBoer, Rebecca, Parvataneni, Rupa, Carliner, Hannah, Kabuubi, Paul, Ayers-Ringler, Jennifer, Rabbitt, Jane, Page, Margaretta, Fedoroff, Anne, Sneed, Penny K., Berger, Mitchel S., McDermott, Michael W., Parsa, Andrew T., Vandenberg, Scott, James, C. David, Lamborn, Kathleen R., Stokoe, David, Haas-Kogan, Daphne A.·2009·Journal of Clinical Oncology

Abstract

Purpose: This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma. The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response. Patients and Methods: Sixty-five eligible adults with newly diagnosed GBM or gliosarcoma were enrolled. We intended to treat patients not currently treated with enzyme-inducing antiepileptic drugs (EIAEDs) with 100 mg/d of erlotinib during XRT and 150 mg/d after XRT. Patients receiving EIAEDs were to receive 200 mg/d of erlotinib during XRT and 300 mg/d after XRT. After XRT, the erlotinib dose was escalated until patients developed tolerable grade 2 rash or until the maximum allowed dose was reached. All patients received temozolomide during and after XRT. Molecular markers of epidermal growth factor receptor (EGFR), EGFRvIII, phosphatase and tensin homolog (PTEN), and methylation status of the promotor region of the MGMT gene were analyzed from tumor tissue. Survival was compared with outcomes from two historical phase II trials. Results: Median survival was 19.3 months in the current study and 14.1 months in the combined historical control studies, with a hazard ratio for survival (treated/control) of 0.64 (95% CI, 0.45 to 0.91). Treatment was well tolerated. There was a strong positive correlation between MGMT promotor methylation and survival, as well as an association between MGMT promotor-methylated tumors and PTEN positivity shown by immunohistochemistry with improved survival. Conclusion: Patients treated with the combination of erlotinib and temozolomide during and following radiotherapy had better survival than historical controls. Additional studies are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.9639

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 378

Metadata

Authors
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., Fedoroff, A., Sneed, P. K., Berger, M. S., McDermott, M. W., Parsa, A. T., Vandenberg, S., James, C. D., Lamborn, K. R., Stokoe, D., & Haas-Kogan, D. A.
Venue
Journal of Clinical Oncology
Published
2009-02-01
Volume
27
Issue
4
Pages
579-584
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2133198620
Cited by
378
References
3
FWCI
15.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. https://app.cochat.ai/papers/10.1200/jco.2008.18.9639
The paper
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., Fedoroff, A., Sneed, P. K., Berger, M. S., McDermott, M. W., Parsa, A. T., Vandenberg, S., James, C. D., Lamborn, K. R., Stokoe, D., & Haas-Kogan, D. A. (2009). Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.18.9639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.